OpenAlex
PricingAboutJobs
Log inGet started
Work

Gefapixant does not have meaningful drug interactions with a MATE1/2K inhibitor or an OATP1B substrate

HTML

Year: 2020
Type: conference-abstract
Source: European Respiratory Journal
DOI: 10.1183/13993003.congress-2020.4565
Authors: Jesse Nussbaum, Jacqueline Mccrea, Azher Hussain, Raymond Evers, Bennett Ma, John Laabs, Carmen Rillera, Graigory Garrett, Yun Li, Marie-Helen Vallee, Deborah Panebianco, S. Aubrey Stoch, Marian Iwamoto
Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Celerion (United States), Novum Pharmaceutical Research Services (United States)
Language: English

Topic: Pharmacogenetics and Drug Metabolism
Subfield: Pharmacology
Field: Pharmacology, Toxicology and Pharmaceutics
Domain: Life Sciences
Keywords: gefapixant, drug-drug interactions, MATE1, OATP1B, hepatic uptake transporters, P2X3 receptor antagonist, chronic cough, pyrimethamine, pitavastatin, pharmacokinetics, renal clearance
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3096412596
Cites:
Cited by:
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms